» Articles » PMID: 30428495

Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry

Abstract

Objective: Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal prognosis. In advanced stages, tumour control by mitotane and cytotoxic chemotherapy is often temporary and salvage treatments are warranted.

Methods: Retrospective cohort study of participants in the prospective European Networks for the Study of Adrenal Tumours (ENSAT) registry. Main outcome measures were best response during treatment, progression-free survival (PFS), both measured according to RECIST 1.1 by two blinded radiologists, and overall survival (OS).

Results: Twenty-seven patients (13 males; median age 44.1 years) progressing after mitotane and a median of 4 further systemic treatments were included. Thalidomide was administered as tolerated with a starting dose of 50 mg and target dose of 200 mg /d. The median interval between treatment initiation and first imaging was 10.5 (4.4-17.5) weeks. The best response to treatment was stable disease (SD, n=2) and progressive disease (n=25), with a median PFS of 11.2 weeks and a median OS of 36.4 weeks. The first patient with SD discontinued treatment due to mild epistaxis and diarrhea after 22.3 weeks. The second patient had SD at the second treatment evaluation after 25.2 weeks and continued thalidomide but then had clinical progression and deceased after 54.3 weeks. In general, thalidomide induced only mild or moderate adverse effects (mainly fatigue and gastrointestinal complaints).

Conclusion: Thalidomide was overall well tolerated but resulted in disease control in only 2/27 (7.4%) patients. In the absence of predictive response markers, thalidomide should only be considered in exceptional cases as a salvage therapy in ACC.

Citing Articles

Management of adrenocortical carcinoma in Slovenia: a real-life analysis of histopathologic markers, treatment patterns, prognostic factors, and survival.

Bokal U, Jeruc J, Kocjan T, Volavsek M, Jerebic J, Rakusa M Radiol Oncol. 2025; 59(1):121-131.

PMID: 40014786 PMC: 11867571. DOI: 10.2478/raon-2025-0013.


Systemic Management of Advanced Adrenocortical Carcinoma.

Russell J Curr Treat Options Oncol. 2024; 25(8):1063-1072.

PMID: 39066856 DOI: 10.1007/s11864-024-01249-6.


Feasibility and Activity of Megestrol Acetate in Addition to Etoposide, Doxorubicin, Cisplatin, and Mitotane as First-Line Therapy in Patients with Metastatic/Unresectable Adrenocortical Carcinoma with Low Performance Status.

Turla A, Lagana M, Abate A, Cremaschi V, Zamparini M, Chitto M Cancers (Basel). 2023; 15(18).

PMID: 37760461 PMC: 10527072. DOI: 10.3390/cancers15184491.


Management of adrenocortical carcinoma: are we making progress?.

Kiesewetter B, Riss P, Scheuba C, Mazal P, Kretschmer-Chott E, Haug A Ther Adv Med Oncol. 2021; 13:17588359211038409.

PMID: 34484430 PMC: 8411624. DOI: 10.1177/17588359211038409.


The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.

Haider M, Ahmad T, Groll J, Scherf-Clavel O, Kroiss M, Luxenhofer R Eur J Drug Metab Pharmacokinet. 2021; 46(5):575-593.

PMID: 34287806 PMC: 8397669. DOI: 10.1007/s13318-021-00700-5.